Celltrion to Develop mRNA Vaccine... "Aiming to Prevent COVID-19 Variants"

"Expanding Technology Areas Beyond COVID-19 to Cancer and Other Diseases"

Incheon Songdo Celltrion Plant 2 Overview. / Incheon - Photo by Hyunmin Kim kimhyun81@

[Asia Economy Reporter Kim Ji-hee] Celltrion is embarking on the development of a next-generation messenger ribonucleic acid (mRNA) vaccine platform.

On the 4th, Celltrion announced that it has signed a contract with the US-based TriLink BioTechnologies and has begun developing the next-generation mRNA vaccine platform. TriLink is a contract development and manufacturing organization (CDMO) based in San Diego, USA, specializing in mRNA platform technology. The company possesses proprietary vectors and third-generation capping technology (CleanCap) essential for mRNA vaccine development. According to Celltrion, TriLink has the capability to provide technology transfer along with clinical materials.

TriLink plans to produce and supply materials capable of conducting Phase 1 and Phase 2 clinical trials to Celltrion by utilizing its antigen sequence verification and proprietary capping technologies. Additionally, it will provide Celltrion with template vectors and mRNA process technologies that meet Good Manufacturing Practice (GMP) standards.

Using these resources, Celltrion will independently develop next-generation vaccines with preventive effects against COVID-19 and various mutant viruses. At the same time, the company plans to accelerate the development of its own mRNA platform using proprietary patented technologies.

Celltrion is currently focusing on developing next-generation COVID-19 mRNA vaccines utilizing antigens from various circulating mutant viruses. Furthermore, it aims to secure foundational technologies through the development of patent-avoiding vectors and improvements in nucleic acid and capping research, and plans to independently conduct large-scale production of Phase 3 clinical trial materials by establishing mRNA process facilities. Notably, Celltrion’s goal with this mRNA platform development is to expand its technological scope beyond COVID-19 to other diseases such as cancer.

A Celltrion representative stated, “Through collaboration with TriLink, which holds core technologies for mRNA vaccines, we have embarked on developing a next-generation mRNA vaccine platform applicable to currently circulating and potential future viruses. Through this collaboration, we will secure Celltrion’s own mRNA platform technology and apply it to new drug development across various fields, striving to expand our new drug portfolio.”

This content was produced with the assistance of AI translation services.